Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors.

Trial Profile

Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
  • Indications Anaplastic astrocytoma; Brain cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Nov 2008 Results from 20 evaluable patients were presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology according to a Burzynski Research Institute media release; results were also reported in the media release.
    • 14 Apr 2008 The expected completion date for this trial is now 1 Dec 2011, according to clinicaltrials.gov.
    • 16 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top